×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARVN – arvinas, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
07:14 am
arvn
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating [Yahoo! Finance]
Medium
Report
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating [Yahoo! Finance]
12/11
04:14 am
arvn
Arvinas (NASDAQ:ARVN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Arvinas (NASDAQ:ARVN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/6
08:05 am
arvn
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Medium
Report
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
11/26
07:15 am
arvn
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:00 am
arvn
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Low
Report
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
11/24
07:00 am
arvn
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
Low
Report
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
11/18
12:30 am
arvn
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks [Yahoo! Finance]
High
Report
Revisiting the Narrative for Arvinas as Analyst Views Shift with New Pipeline and Partner Risks [Yahoo! Finance]
11/10
09:25 am
arvn
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Stephens from $14.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Arvinas (NASDAQ:ARVN) had its price target raised by analysts at Stephens from $14.00 to $15.00. They now have an "overweight" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/8
06:36 am
arvn
Form 8-K ARVINAS, INC. For: Dec 06
Medium
Report
Form 8-K ARVINAS, INC. For: Dec 06
11/14
04:13 pm
arvn
Form SCHEDULE 13G ARVINAS, INC. Filed by: D. E. SHAW & CO, L.P.
Medium
Report
Form SCHEDULE 13G ARVINAS, INC. Filed by: D. E. SHAW & CO, L.P.
11/14
04:11 pm
arvn
Form SCHEDULE 13G/A ARVINAS, INC. Filed by: CITADEL ADVISORS LLC
Medium
Report
Form SCHEDULE 13G/A ARVINAS, INC. Filed by: CITADEL ADVISORS LLC
11/7
04:20 pm
arvn
Form 4 ARVINAS, INC. For: Nov 07 Filed by: Loomis David K
Medium
Report
Form 4 ARVINAS, INC. For: Nov 07 Filed by: Loomis David K
11/5
04:08 pm
arvn
Form 10-Q ARVINAS, INC. For: Sep 30
Medium
Report
Form 10-Q ARVINAS, INC. For: Sep 30
11/5
07:03 am
arvn
Form 8-K ARVINAS, INC. For: Nov 05
Low
Report
Form 8-K ARVINAS, INC. For: Nov 05
10/24
04:02 pm
arvn
Form 8-K ARVINAS, INC. For: Oct 24
Medium
Report
Form 8-K ARVINAS, INC. For: Oct 24
10/20
06:07 am
arvn
Form 8-K ARVINAS, INC. For: Oct 20
Low
Report
Form 8-K ARVINAS, INC. For: Oct 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form S-8 ARVINAS, INC.
18.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.560 ZacksConsensus N/A ActVsEst N/A - N/A
-18.4%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: